The potency and selectivity of these compounds in breast cancers is determined by their chemical composition as well as the overexpression of AhR and SULT1A1 proteins (Huang et al., 2014; Gilbert et al., 2017; Baker et al., 2020; Gilbert et al., 2020; Safe and Zhang, 2022), with the latter presenting as a potential clinical biomarker for targeted therapy (Huang et al., 2014). Here, AHR is linked to breast cancer.